MediWound Ltd.

NASDAQ:MDWD

Biotechnology

Healthcare
$13.61 -0.60%

-$0.09 today

Market cap
$175.71M
Beta
0.15
P/E (TTM)
-7.0
EPS (TTM)
-$2.03
52W Low $13.54High $21.26

Volume 0.17M

Average 0.09M

MDWD Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

MediWound Ltd.NASDAQ: MDWD

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit dips below year-ago levels

Q1 FY2026 gross profit of $323K fell 56.2% year over year, behind the +2.7% change in trailing-twelve-month gross profit. Sequentially, it rose 16.2% from the prior quarter. Over 3 fiscal years it compounded at -37.2% a year.

Context

  • Gross profit amounted to 19.2% of revenue in FY2025, up 6.2 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -56.2% toward the trailing-twelve-month pace of +2.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$323K+16.2% QoQ
Last fiscal yearDec 2025
$3.25M+23.5% YoY
LTMMar 2026
$2.84M+2.7% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-56.2%——
1 year+23.5%——
3-year CAGR-37.2%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
3.25M USD
Year-over-year change
+23.5%
4-year CAGR
-22.0%

Gross Profit vs competitors

How MDWD compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +2.7% is the 3rd highest of 6, against a peer median of -13.6%.
  • Gross profit amounts to 19.6% of revenue for MDWD, versus a peer median of 95.6%.
MDWD Competitors
Gross Profit for MDWD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVVDInvivyd, Inc.LTM Mar 2026$51.41M USD+50.2%—92.0%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$32.49M USD+1115.8%+118.1%99.3%
MDWDMediWound Ltd.LTM Mar 2026$2.84M USD+2.7%-37.2%19.6%
IVAInventiva S.A.FY2025€1.51M EUR-83.6%-55.4%33.7%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$0 USD———
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$0 USD———
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026-$31.98K USD———
TARAProtara Therapeutics, Inc.LTM Mar 2026-$90K USD———
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026-$151.18K USD-13.6%——
RNACCartesian Therapeutics, Inc.LTM Mar 2026-$11.02M USD-132.3%-70.5%621.0%
Peer median (excluding MDWD) —-13.6%-55.4%95.6%

Competitors are the stored peer set for MDWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue23.76M26.5M18.69M20.22M16.96M
Cost of Revenue14.99M13.33M15.11M17.59M13.71M
Gross Profit8.77M13.17M3.58M2.63M3.25M
Gross Margin36.9%49.7%19.1%13.0%19.2%
Research & Development10.26M10.18M7.47M8.88M14.32M
Selling, General & Admin9.45M10.37M11.38M12.91M13.93M
Operating Expenses19.99M20.83M19.08M22.02M28.53M
Depreciation & Amortization1.24M1.27M1.3M1.48M1.86M
EBITDA(11.38M)(18.25M)(4.8M)(27.93M)(21.47M)
EBITDA Margin-47.9%-68.9%-25.7%-138.1%-126.6%
Operating Income(11.22M)(7.66M)(15.5M)(19.38M)(25.28M)
Operating Margin-47.2%-28.9%-83.0%-95.8%-149.1%
Interest Income11K270K2.34M2.05M1.86M
Interest Expense167K162K335K561K663K
Other Income / Expenses(2.3M)(11.86M)8.97M(10.78M)1.57M
Income Before Tax(13.52M)(19.52M)(6.53M)(30.16M)(23.71M)
Pre-Tax Margin-56.9%-73.7%-35.0%-149.2%-139.8%
Income Tax Expense27K78K185K61K169K
Net Income(13.55M)(19.6M)(6.72M)(30.22M)(23.88M)
Net Margin-57.0%-74.0%-35.9%-149.5%-140.8%
EPS (Basic)(3.48)(3.93)(0.75)(3.03)(2.10)
EPS (Diluted)(3.48)(3.93)(0.75)(3.03)(2.10)
Weighted Avg Shares3.89M4.99M9.01M9.96M11.38M
Weighted Avg Shares (Diluted)3.89M4.99M9.01M9.96M11.38M

MediWound Ltd.

NASDAQ:MDWD

Intrinsic Alpha fair value

Locked

Current Price

$13.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.